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characteristics of the orphan drugs (OD) with the non-Orphan
drugs approved by the FDA in the period 1983–2007.
METHODS: All new chemical entities (NCE) approved by the
FDA in the study period were included in the study. Data derived
from the FDA’s Orange Book (OB). Differences between group
means were assessed using the t-test. Differences in proportions
were evaluated using chi-square and Fisher’s exact test.
RESULTS: Between January 4, 1983 and October 3, 2007 the
FDA granted 1749 OD designations and 315 OD approvals for
marketing. NCEs accounted for 17.7% of OD designations and
53.7% of OD approvals. The FDA approved 635 NCEs in the
study period, out of which 17.5% had OD status at the ﬁrst
NDA approval. Sponsors of ODs were more likely (p < 0.001) to
be US companies as compared to non-US companies (64.0% vs.
54.4%) and to have one NCE approval as compared to multiple
NCE during the study period (43.2% vs. 17.6%). ODs were less
likely (p < 0.001) to have at least one patent listed in the OB in
comparison with non-ODs (62.2% vs. 82.8%). ODs had less
patents listed in the OB than non-ODs (mean 1.7 vs. 2.3)
(p < 0.005). Exclusivity period was longer than the patent period
for 41.4% of the ODs and 21.4% of the non-ODs that had
patents listed in the OB (p < 0.001). ODs had less generic com-
petition than non-ODs (18.0% vs. 29.6%) (p < 0.05). CON-
CLUSION: US companies and companies with only one NCE
approval were more likely to use the Orphan drug regulatory
system. Orphan drugs have less number of patents, more exclu-
sivity protection and less generic competition than non-orphan
drugs.
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OBJECTIVE: To compare health care utilization changes
between Medicare beneﬁciaries with two prescription drug
beneﬁt structures who did and did not reach their respective Part
D drug beneﬁt spend threshold in 2006. METHODS: A retro-
spective analysis of a cohort of 28,392 Medicare Advantage
beneﬁciaries continuously enrolled into two distinct drug beneﬁt
structures for the year prior to and after implementation of the
Medicare Part D beneﬁt. The ﬁrst beneﬁt group (Silver) had the
Part D standard drug beneﬁt threshold ($2250) while the second
(Gold) had an enhanced beneﬁt with a higher threshold ($3500).
Poisson, zero-inﬂated Poisson, and negative binomial modeling
were used to compare post-implementation utilization rates with
adjustment for pre-period utilization, demographics and morbid-
ity burden. RESULTS: A total of 1237 (6%) Silver and 526 (8%)
Gold beneﬁciaries reached their threshold. Among both groups,
beneﬁciaries who reached their threshold had greater morbidity
burden and higher rates of pre-period inpatient admissions and
medical ofﬁce and ED visits (all p < 0.001). Among beneﬁciaries
who reached their threshold, there was no change in inpatient
and ED (both p > 0.05) but an increase in medical ofﬁce visit
(p < 0.001) utilization rates in comparable 6-month periods
before and after reaching their threshold. Sub-analyses indicated
that beneﬁciaries with the highest morbidity burden experienced
higher utilization rates (all p < 0.05), but there were no differ-
ences between groups (all p > 0.05). Beneﬁciaries in both groups
who did reach their threshold had higher post-period utilization
rates (all p < 0.001) regardless of age and morbidity burden and
were more likely to die (p < 0.001) compared to beneﬁciaries
who did not reach their threshold. CONCLUSION: Although
many Medicare beneﬁciaries navigate their drug spend threshold
without experiencing increased health care utilization, those with
high morbidity burdens are at risk of increased health care uti-
lization and the potential for adverse outcomes. It is imperative
that strategies be developed that help safeguard vulnerable Medi-
care beneﬁciaries.
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OBJECTIVE: Investigate the variation in Medicare claim-paying
agents (carriers) reimbursement to physicians for chemotherapy
and evaluate the inﬂuence of Medicare carrier chemotherapy
reimbursement on G-CSF choice. G-CSF is an expensive drug to
manage febrile neutropenia with uncertain beneﬁts. METHODS:
Using the national SEER-Medicare linked database, we studied
patients 66 years or older diagnosed as NHL in one of the 13
SEER registry areas from 1994–2002. We grouped counties
within SEER based on Medicare carrier coverage. We then esti-
mated a regression model describing total physician reimburse-
ment during the ﬁrst cycle of chemotherapy (total Medicare part
B and Medicare outpatient reimbursements within 21 days of the
chemotherapy start date) to construct average Medicare chemo-
therapy physician reimbursement measures for these county
groups. Logistic regression was performed to assess the inﬂuence
of Medicare carrier chemotherapy reimbursement on the use of
G-CSF. RESULTS: F test from the regression model showed
statistically signiﬁcant variation in the reimbursement for ﬁrst
cycle chemotherapy by counties grouped by carrier coverage (P
value = 0.0017). We found that Medicare carrier-related chemo-
therapy reimbursement had a non-linear relationship with the
use of G-CSF. Both linear and squared reimbursement terms were
statistically signiﬁcant. An increase in chemotherapy reimburse-
ment from initially low reimbursement levels resulted in a
decrease in the use of G-CSF and this relationship went away at
higher chemotherapy reimbursement levels. CONCLUSION:
Medicare physician reimbursement for chemotherapy varies
across Medicare carriers and this variation affects the decision of
physicians to prescribe G-CSF. At low chemotherapy reimburse-
ment levels, increases in chemotherapy reimbursements decreases
G-CSF prescribing. Physicians appear to compensate for lower
reimbursements by increasing the intensity of their services.
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OBJECTIVE: Little is known about how Medicare Part D utili-
zation varies based on subjects’ pre-Part D prescription coverage
and comorbidities. METHODS: We examined claims from a
national pharmacy chain from 2005 and 2006 accounting for
approximately 15% of the U.S. prescription drug market. We
focused on beneﬁciaries ages 66–79 as of January 1, 2006. We
focused on the association between pre-Part D insurance gener-
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osity, comorbid burden using a method of risk adjustment based
on pharmacy claims, and Part D uptake after adjusting for
patients’ demographic characteristics, characteristics of pre-Part
D prescription use (average 2005 annual copayments, number of
prescriptions, drug utilization in pill-days, number of treatment
classes as reported in the store data), pre-Part D Medicaid eligi-
bility, and zip code linked USA Census data. RESULTS: After
multivariate adjustment, each 10% increase in 2005 insurance
generosity was associated with a 16% lower likelihood of Part D
utilization and each standard deviation increase in comorbid
score was associated with an 8% greater likelihood of Part D
utilization. Beneﬁciaries with the lowest yet positive insurance
generosity with the greatest comorbid burden were up to 2.5
times more likely to utilize Part D than people who had generous
insurance and were the healthiest before the introduction of the
program (60.65% vs. 37.56%, p < 0.001). Results were robust
to numerous sensitivity analyses. CONCLUSION: We ﬁnd sig-
niﬁcantly higher rates of beneﬁt adoption among subjects with
low pre-Part D prescription coverage and high pre-Part D comor-
bid burden. Our ﬁndings highlight the fact that implementation
and uptake of changes in health policy are seldom uniform.
These results also may be useful in welfare analyses of Part D,
and they demonstrate the importance of considering non-random
selection into Part D when considering the impact of Part D on
processes or outcomes of care.
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OBJECTIVE: To evaluate the effect of Medicare new drug beneﬁt
(Part D) on utilization of psychotropic medications and the con-
sequent ﬁnancial burden for elderly. METHODS: The effect of
Medicare Part D was measured using 24 months pharmacy
claims collected from one of the largest retail pharmacy chains in
the United States. Among the approximately 70 million individu-
als who ﬁlled prescriptions at the pharmacy chain in 2006, 11%
were 65 years or older. Segmented regression of interrupted
time series analysis was employed to evaluate population level
changes in the utilization of three most commonly used psycho-
tropic therapeutic categories among elderly, namely antidepres-
sants, antipsychotics and benzodiazepines. RESULTS: Since Part
D came into effect, the proportion of out-of-pocket payment in
total pharmacy reimbursement decreased 18% for antidepres-
sants (net saving: $4.5 per prescription) and 21% for antipsy-
chotics (net saving: $5.7 per prescription). In contrast, the out-
of-pocket share the elderly paid for benzodiazepines increased
19% (net increase: $2.8 per prescription). Part D implementation
was associated with signiﬁcant month-to-month increase in use
of antidepressants [1679 prescriptions per month (95%CI:719,
2639)] and antipsychotics [567 prescriptions per month (95%
CI:413, 720)]. By December 2006, the antidepressant and antip-
sychotic prescriptions ﬁlled by seniors grew 7% (from 273,166
to 293,590 prescriptions per month, P < 0.001) and 18% (from
41,079 to 48,276 prescriptions per month, P < 0.001) respec-
tively as compared to the expected level estimated based on prior
Part D trend. In contrast, Part D led to an immediate and sus-
tained drop of 5% (from 238,961 to 226,622 prescriptions per
month, P < 0.001) in benzodiazepine prescriptions ﬁlled by
elderly. CONCLUSION: Our ﬁndings revealed that Medicare
Part D improved the access to psychotropic medications covered
under plan through reducing out-of-pocket expenses. However,
the ﬁnancial burden related to psychotropic medications
excluded from the Part D formulary, such as benzodiazepines,
has signiﬁcantly increased.
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The aim of this study was to assess the Rasch measurement
properties of the EQ-5D in respondents with most prevalent
chronic conditions. Medical Expenditures Panel Survey (MEPS)
respondents’ age  18 with complete EQ-5Ds from 2003 were
extracted (n = 19,439). Eleven subgroups were identiﬁed using
the primary ICD-9-CM code for the top 10 chronic conditions
(hypertension, diabetes, depression, back disorder, arthropathy,
cholesterol, asthma, sinusitis, anxiety and joint disorder) as well
as healthy persons (n = 8021). Respondents with perfect scores
demonstrating ceiling (n = 3911) and ﬂoor effects (n = 3) were
removed to ensure uncertainty in the responses. Coding reﬂected
that higher scores represent healthier respondents. The Rasch
rating scale model was used to estimate one set of thresholds for
all items. Unidimensionality was assessed using a z-score ﬁt sta-
tistic, point-biserial correlations and Rasch residual factor analy-
sis. Differential item functioning (DIF) was investigated in a
pooled analysis of the 11 subgroups. Qualitative advances of the
thresholds and positive point-biserial correlations were found
on the EQ-5D items in all subgroups. Residual factor analysis
revealed that a single factor explained between 74.9% and
94.4% of the variance. Further, respondents with different
diseases demonstrated different orders of item difﬁculty. How-
ever, the item “anxiety/depression” consistently showed misﬁt
(z-score > 2.0) in all subgroups. Overall, differential item func-
tioning was found across the 11 subgroups, suggesting that
respondents with different health conditions endorsed items with
different frequency. For the most part, items in the EQ-5D con-
tribute to a single underlying construct and may be used to
evaluate different disease conditions. However, consistent item
misﬁt of the “anxiety/depression” item in all subgroups suggests
that a possible modiﬁcation on this item may be needed.
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The value of qualitative research in the development of Patient-
Reported Outcome (PRO) measures has been recognized for
many years. Very little information is available, however, in the
PRO ﬁeld on the conduct and analysis of qualitative research
compared to the plethora of literature that is readily available on
psychometrics. More recently, the focus has been placed on the
concepts being measured and their meaning, and not in terms
of correlation coefﬁcients or factorial structure, but in their
authenticity for patients. This paper that is authored by an inter-
national, interdisciplinary group of psychologists, psychometri-
cians, regulatory experts, a physician, and a sociologist presents
a method for developing PROs that are based on a foundation of
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